A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine

Clinical Pharmacokinetics

Volumn 42, Issue 2, 2003, Pages 179-192

  Yin, Ophelia Q P ^a   Tomlinson, Brian ^a   Chow, Albert H L ^a   Chow, Moses S S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

RANITIDINE;

ACCURACY; ADULT; ARTICLE; COMPARTMENT MODEL; CORRELATION COEFFICIENT; CURVE FITTING; DRUG ABSORPTION; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTESTINE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH EMPTYING; VALIDATION PROCESS;

ADULT; ALGORITHMS; AREA UNDER CURVE; BIOPHARMACEUTICS; COMPUTER SIMULATION; HALF-LIFE; HISTAMINE H2 ANTAGONISTS; HUMANS; INTESTINAL ABSORPTION; MALE; MODELS, BIOLOGICAL; RANITIDINE;

EID: 0037275847     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342020-00005     Document Type: Article

References (33)

1. Grag DC, Weidder DJ, Eshelnan FN, et al. Ranitidine bioavailability and kinetics in normal male subjects. Clin Pharmacol Ther 1981; 33: 445-51
2. Van Hecken AM, Tjandramaga TB, Mullie A, et al. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. Br J Clin Pharmacol 1982; 14: 195-200
3. Walkenstein SS, Dubb JW, Randolph WC, et al. Bioavailability of cimetidine in man. Gastroenterology 1978; 74: 360-5
4. Kroemer H, Klotz U. Pharmacokinetics of famotidine in man. Int J Clin Pharmacol Ther Toxicol 1987; 25: 458-63
5. Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration: application of moment analysis. Eur J Clin Pharmacol 1984; 26: 197-207
6. Plusquellec Y, Campistrom G, Staveris S, et al. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 1987; 15: 225-39
7. Brockmeier D, Grigoleit HG, Leonhardt H. The absorption of piretanide from the gastro-intestinal tract is site-dependent. Eur J Clin Pharmacol 1986; 30: 79-82
8. Wang YX, Roy A, Sun L, et al. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 1999; 27: 855-9
9. Miller R. Pharmacokinetics and bioavailability of ranitidine in humans. J Pharm Sci 1984; 73: 1376-9
10. Lennernas H, Regardh CG. Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm Res 1993; 10: 727-31
11. Kaneniwa N, Funaki T, Furuta S, et al. Study of the absorption site of cimetidine. J Pharmacobiodyn 1986; 9: 321-6
12. Grematte T, EL-Desoky E, Klotz U. Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 1994; 46: 253-9
13. Oberle RL, Amidon GL. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine: an explanation for the double peak phenomenon of cimetidine in humans. J Pharamcokinet Biopharm 1987; 15: 529-44
14. Klotz U, Walker S. Biliary excretion of H2-receptor antagonists. Eur J Clin Pharmacol 1990; 39: 91-2
15. Suttle AB, Pollack GM, Brouwer KLR. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm Res 1992; 9: 350-6
16. Witcher JW, Boudinot FD. Application and simulation of a discontinuous oral absorption pharmacokinetic model. Pharm Res 1996; 13: 1720-4
17. Plusquellec Y, Efthymiopoulos C, Duthil P, et al. A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption. Med Eng Phys 1999; 21: 525-32
18. Suttle AB, Brouwer KLR. Gastrointestinal transit and distribution of ranitidine in the rat. Pharm Res 1995; 12: 1316-21
19. Woodtli W, Owyang C. Duodenal pH governs interdigestive motility in humans. Am J Physiol 1995; 268: G146-52
20. Vantrappen G, Janssens J, Peeters TL, et al. Motilin and the interdigestive migrating motor complex in man. Dig Dis Sci 1979; 24: 497-500
21. Dooley CP, Lorenzo CD, Valenzuela JE. Variability of migrating motor complex in humans. Dig Dis Sci 1992; 37: 723-8
22. Fleckenstein P, Oiguard A. Electrical spike activity in the human small intestine: a multiple electrode study of fasting diurnal variation. Am J Dig Dis 1978; 23: 776-80
23. Itoh Z, Sekiguchi T. Interdigestive motor activity in health and disease. Scan J Gastroenterol 1983; 18 Suppl. 82: 121-34
24. Dressman JB, Berardi RR, Elta GH, et al. Absorption of flurbiprofen in the fed and fasted states. Pharm Res 1992; 9: 901-7
25. Lipka E, Lee ID, Langguth P, et al. Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modelling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 1995; 23: 267-85
26. Murata K, Noda K, Kohno K, et al. Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models. J Pharm Sci 1987; 76: 109-13
27. Al-Khamis KI, El-Sayed YM, Al-Rashood KA, et al. High performance liquid chromatographic determination of ranitidine in plasma. J Liq Chromatogr 1995; 18: 277-86
28. Van Den Hof JM. Structural identifiability of linear compartmental system. IEEE Trans Automat Contr 1998; 43: 800-18
29. Evans ND, Godfrey KR, Chapman MJ, et al. An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J Pharmacokinet Biopharm 2001; 28: 93-105
30. Hunt JN, MacDonald I. The influence of volume on gastric emptying. J Physiol 1954; 126: 459-74
31. Oberle RL, Chen TS, Lloyd C, et al. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterol 1990; 99: 1275-82
32. Shim CK, Hong JS. Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects. J Pharm Res 1989; 78: 990-3
33. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982